Sarizotan
Pre-clinicalTerminated 0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neuroleptic-induced Tardive Dyskinesia
Conditions
Neuroleptic-induced Tardive Dyskinesia
Trial Timeline
Dec 1, 2004 → Mar 1, 2008
NCT ID
NCT00310661About Sarizotan
Sarizotan is a pre-clinical stage product being developed by Merck for Neuroleptic-induced Tardive Dyskinesia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00310661. Target conditions include Neuroleptic-induced Tardive Dyskinesia.
What happened to similar drugs?
0 of 1 similar drugs in Neuroleptic-induced Tardive Dyskinesia were approved
Approved (0) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
3
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00310661 | Pre-clinical | Terminated |
Competing Products
1 competing product in Neuroleptic-induced Tardive Dyskinesia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Gabapentin | Pfizer | Phase 3 | 32 |